The vector with SMN1 is administered intravenously once, and Zolgensma therapy shows the best results, administered soon after birth, before the manifestation of clinical symptoms of SMA, because apparently there is a delay in the development of motor neurons for several months. Here, SMN1 is linked to proximal spinal muscular atrophy.